Departments of Pediatrics.
Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY.
J Pediatr Hematol Oncol. 2024 Oct 1;46(7):e531-e533. doi: 10.1097/MPH.0000000000002939. Epub 2024 Aug 22.
Outcomes for high-risk neuroblastoma have improved with the addition of antidisialoganglioside (GD2) antibody-mediated immunotherapy to multimodality therapy. Urticaria is an expected side effect of anti-GD2 immunotherapy. Rarely, despite maximal use of antihistamines and H2 receptor antagonists, refractory urticaria can result in impaired quality of life, and delays or discontinuation of immunotherapy. The anti-IgE monoclonal antibody, omalizumab, is approved for the treatment of asthma and chronic spontaneous urticaria. We successfully managed grade 3, naxitamab-related urticaria refractory to standard management in 2 patients using omalizumab, allowing for continued anti-GD2 immunotherapy. Omalizumab did not impact antitumor activity or immunogenicity of naxitamab.
高危神经母细胞瘤的治疗效果已经随着将抗唾液酸神经节苷脂（GD2）抗体介导的免疫疗法加入到多模式疗法而得到改善。荨麻疹是抗 GD2 免疫疗法的一种预期副作用。尽管使用了最大剂量的抗组胺药和 H2 受体拮抗剂，仍有极少数情况下会出现难治性荨麻疹，导致生活质量受损，并延迟或停止免疫治疗。抗 IgE 单克隆抗体奥马珠单抗已被批准用于治疗哮喘和慢性自发性荨麻疹。我们成功地使用奥马珠单抗治疗了 2 例对标准治疗难治的 naxitamab 相关 3 级荨麻疹，从而能够继续进行抗 GD2 免疫治疗。奥马珠单抗并未影响 naxitamab 的抗肿瘤活性或免疫原性。
